Compare Q & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | Q | ONC |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7B | 31.4B |
| IPO Year | N/A | N/A |
| Metric | Q | ONC |
|---|---|---|
| Price | $144.62 | $299.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $119.80 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 1.9M | 293.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.87 | $723.76 |
| Revenue Next Year | $7.64 | $15.04 |
| P/E Ratio | ★ $29.99 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.81 | $249.12 |
| 52 Week High | $177.28 | $385.22 |
| Indicator | Q | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 58.10 |
| Support Level | $138.39 | $289.57 |
| Resistance Level | $171.95 | $310.50 |
| Average True Range (ATR) | 8.75 | 7.73 |
| MACD | -2.22 | 3.38 |
| Stochastic Oscillator | 23.30 | 66.12 |
Qnity is a specialty chemicals company created in 2025 after being spun off from DuPont. It sells chemicals and materials to the semiconductor industry, which generates the majority of sales, and also the electronics industry. Qnity specializes in materials science, including supplying key materials required to manufacture semiconductors and interconnected devices.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.